Which has higher earnings and valuation, PDEX or DRIO?

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 3.12 $8.98M $3.62 18.00 DarioHealth $22.36M 2.50 -$41.71M -$8.88 N/A

Is PDEX or DRIO more profitable?

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% DarioHealth -192.23% -60.52% -37.08%

Which has better valuation and earnings, EMBC or DRIO?

Embecta has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.18 $95.40M $1.90 1.75 DarioHealth $22.36M 2.50 -$41.71M -$8.88 N/A

Is EMBC or DRIO more profitable?

Embecta has a net margin of 10.73% compared to DarioHealth's net margin of -192.23%. Embecta's return on equity of -23.96% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% DarioHealth -192.23% -60.52% -37.08%

DarioHealth (DRIO) Competitors

$7.65 0.00 (0.00%)

Closing price 03:58 PM Eastern

Extended Trading

$7.49 -0.16 (-2.09%)

As of 04:10 PM Eastern

Compare

DRIO vs. SMTI, PDEX, TLSI, KRMD, and EMBC

Should you buy DarioHealth stock or one of its competitors? MarketBeat compares DarioHealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DarioHealth include Sanara MedTech (SMTI), Pro-Dex (PDEX), TriSalus Life Sciences (TLSI), KORU Medical Systems (KRMD), and Embecta (EMBC). These companies are all part of the "medical equipment" industry.

How does DarioHealth compare to Sanara MedTech?

DarioHealth (NASDAQ:DRIO) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DarioHealth currently has a consensus price target of $10.50, suggesting a potential upside of 37.25%. Sanara MedTech has a consensus price target of $34.00, suggesting a potential upside of 62.14%. Given Sanara MedTech's higher possible upside, analysts clearly believe Sanara MedTech is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sanara MedTech	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

DarioHealth has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

In the previous week, Sanara MedTech had 2 more articles in the media than DarioHealth. MarketBeat recorded 3 mentions for Sanara MedTech and 1 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.94 beat Sanara MedTech's score of 0.63 indicating that DarioHealth is being referred to more favorably in the media.

Company	Overall Sentiment
DarioHealth	Positive
Sanara MedTech	Positive

Sanara MedTech has higher revenue and earnings than DarioHealth. Sanara MedTech is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.50	-$41.71M	-$8.88	N/A
Sanara MedTech	$103.12M	1.86	-$37.56M	-$3.77	N/A

Sanara MedTech has a net margin of -31.23% compared to DarioHealth's net margin of -192.23%. Sanara MedTech's return on equity of -3.19% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Summary

Sanara MedTech beats DarioHealth on 11 of the 15 factors compared between the two stocks.

How does DarioHealth compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Pro-Dex has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

In the previous week, Pro-Dex had 2 more articles in the media than DarioHealth. MarketBeat recorded 3 mentions for Pro-Dex and 1 mentions for DarioHealth. Pro-Dex's average media sentiment score of 1.15 beat DarioHealth's score of 0.94 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Overall Sentiment
Pro-Dex	Positive
DarioHealth	Positive

Pro-Dex currently has a consensus target price of $70.00, indicating a potential upside of 7.41%. DarioHealth has a consensus target price of $10.50, indicating a potential upside of 37.25%. Given DarioHealth's higher probable upside, analysts plainly believe DarioHealth is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
DarioHealth	-192.23%	-60.52%	-37.08%

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.12	$8.98M	$3.62	18.00
DarioHealth	$22.36M	2.50	-$41.71M	-$8.88	N/A

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 3.5% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Pro-Dex beats DarioHealth on 12 of the 15 factors compared between the two stocks.

How does DarioHealth compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 135.85%. DarioHealth has a consensus target price of $10.50, indicating a potential upside of 37.25%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe TriSalus Life Sciences is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, TriSalus Life Sciences had 2 more articles in the media than DarioHealth. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 1 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.94 beat TriSalus Life Sciences' score of 0.70 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
TriSalus Life Sciences	Positive
DarioHealth	Positive

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 3.5% of DarioHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TriSalus Life Sciences has higher revenue and earnings than DarioHealth. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	4.33	-$39.23M	-$1.41	N/A
DarioHealth	$22.36M	2.50	-$41.71M	-$8.88	N/A

TriSalus Life Sciences has a net margin of -60.85% compared to DarioHealth's net margin of -192.23%. TriSalus Life Sciences' return on equity of 0.00% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
DarioHealth	-192.23%	-60.52%	-37.08%

TriSalus Life Sciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Summary

TriSalus Life Sciences beats DarioHealth on 11 of the 16 factors compared between the two stocks.

How does DarioHealth compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

In the previous week, KORU Medical Systems had 1 more articles in the media than DarioHealth. MarketBeat recorded 2 mentions for KORU Medical Systems and 1 mentions for DarioHealth. KORU Medical Systems' average media sentiment score of 0.94 equaled DarioHealth'saverage media sentiment score.

Company	Overall Sentiment
KORU Medical Systems	Positive
DarioHealth	Positive

KORU Medical Systems currently has a consensus target price of $7.25, suggesting a potential upside of 84.24%. DarioHealth has a consensus target price of $10.50, suggesting a potential upside of 37.25%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, research analysts plainly believe KORU Medical Systems is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

KORU Medical Systems has a net margin of -5.27% compared to DarioHealth's net margin of -192.23%. KORU Medical Systems' return on equity of -13.61% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
DarioHealth	-192.23%	-60.52%	-37.08%

KORU Medical Systems has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by company insiders. Comparatively, 3.5% of DarioHealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

KORU Medical Systems has higher revenue and earnings than DarioHealth. KORU Medical Systems is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13M	4.39	-$2.64M	-$0.05	N/A
DarioHealth	$22.36M	2.50	-$41.71M	-$8.88	N/A

Summary

KORU Medical Systems beats DarioHealth on 13 of the 15 factors compared between the two stocks.

How does DarioHealth compare to Embecta?

Embecta (NASDAQ:EMBC) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Embecta has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.18	$95.40M	$1.90	1.75
DarioHealth	$22.36M	2.50	-$41.71M	-$8.88	N/A

93.8% of Embecta shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Embecta presently has a consensus price target of $11.00, indicating a potential upside of 231.33%. DarioHealth has a consensus price target of $10.50, indicating a potential upside of 37.25%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Embecta had 4 more articles in the media than DarioHealth. MarketBeat recorded 5 mentions for Embecta and 1 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.94 beat Embecta's score of 0.20 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Embecta	Neutral
DarioHealth	Positive

Embecta has a net margin of 10.73% compared to DarioHealth's net margin of -192.23%. Embecta's return on equity of -23.96% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
DarioHealth	-192.23%	-60.52%	-37.08%

Embecta has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

Embecta beats DarioHealth on 10 of the 16 factors compared between the two stocks.

Get DarioHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRIO vs. The Competition

Export

Metric	DarioHealth	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.94M	$7.25B	$6.47B	$12.54B
Dividend Yield	N/A	1.23%	2.69%	5.22%
P/E Ratio	-0.86	45.06	22.39	24.18
Price / Sales	2.50	74.02	520.79	112.26
Price / Cash	N/A	24.22	41.34	57.13
Price / Book	0.76	7.15	9.84	6.72
Net Income	-$41.71M	$159.22M	$3.57B	$337.19M
7 Day Performance	-0.05%	0.91%	-1.16%	0.48%
1 Month Performance	5.26%	3.99%	3.85%	5.07%
1 Year Performance	-42.95%	1.56%	27.40%	34.25%

DarioHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRIO DarioHealth	2.3364 of 5 stars	$7.65 flat	$10.50 +37.3%	-46.5%	$55.94M	$22.36M	N/A	200	Gap Down
SMTI Sanara MedTech	1.7598 of 5 stars	$23.24 +1.3%	$34.00 +46.3%	-26.9%	$212.33M	$107.48M	N/A	60
PDEX Pro-Dex	2.5445 of 5 stars	$65.30 +0.2%	$70.00 +7.2%	+70.1%	$208.31M	$66.59M	18.04	140	News Coverage Positive News
TLSI TriSalus Life Sciences	3.8465 of 5 stars	$3.16 -1.8%	$7.50 +137.1%	-35.9%	$196.54M	$45.15M	N/A	106
KRMD KORU Medical Systems	4.299 of 5 stars	$4.25 +1.2%	$7.25 +70.6%	+45.2%	$195.22M	$43.26M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRIO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DarioHealth (DRIO) Competitors

DRIO vs. SMTI, PDEX, TLSI, KRMD, and EMBC

How does DarioHealth compare to Sanara MedTech?

Summary

How does DarioHealth compare to Pro-Dex?

Summary

How does DarioHealth compare to TriSalus Life Sciences?

Summary

How does DarioHealth compare to KORU Medical Systems?

Summary

How does DarioHealth compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DarioHealth (DRIO) Competitors

DRIO vs. SMTI, PDEX, TLSI, KRMD, and EMBC

How does DarioHealth compare to Sanara MedTech?

Do insiders & institutionals have more ownership in DRIO or SMTI?

Do analysts recommend DRIO or SMTI?

Which has more risk and volatility, DRIO or SMTI?

Does the media refer more to DRIO or SMTI?

Which has preferable valuation & earnings, DRIO or SMTI?

Is DRIO or SMTI more profitable?

Summary

How does DarioHealth compare to Pro-Dex?

Which has more risk and volatility, PDEX or DRIO?

Does the media prefer PDEX or DRIO?

Do analysts recommend PDEX or DRIO?

Is PDEX or DRIO more profitable?

Which has higher earnings and valuation, PDEX or DRIO?

Do insiders & institutionals believe in PDEX or DRIO?

Summary

How does DarioHealth compare to TriSalus Life Sciences?

Do analysts rate TLSI or DRIO?

Does the media prefer TLSI or DRIO?

Do insiders and institutionals have more ownership in TLSI or DRIO?

Which has preferable valuation and earnings, TLSI or DRIO?

Is TLSI or DRIO more profitable?

Which has more risk and volatility, TLSI or DRIO?

Summary

How does DarioHealth compare to KORU Medical Systems?

Does the media prefer KRMD or DRIO?

Do analysts rate KRMD or DRIO?

Is KRMD or DRIO more profitable?

Which has more volatility and risk, KRMD or DRIO?

Do institutionals & insiders believe in KRMD or DRIO?

Which has stronger earnings and valuation, KRMD or DRIO?

Summary

How does DarioHealth compare to Embecta?

Which has better valuation and earnings, EMBC or DRIO?

Do institutionals and insiders believe in EMBC or DRIO?

Do analysts rate EMBC or DRIO?

Does the media prefer EMBC or DRIO?

Is EMBC or DRIO more profitable?

Which has more risk & volatility, EMBC or DRIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools